TrimRx's Blog
Pelvic Floor Health and GLP-1 Weight Loss: What Actually Changes
Losing weight on a GLP-1 medication takes real, measurable pressure off your pelvic floor, and for many people that translates into fewer symptoms like…
Does GLP-1 Weight Loss Improve Erectile Dysfunction? What Men Should Know
For many men, losing a significant amount of weight on a GLP-1 medication does improve erectile function, though the reason has more to do…
What Is Amycretin? Novo’s Next-Generation Amylin-GLP-1 Drug
Amycretin is an investigational obesity drug from Novo Nordisk that combines two appetite-regulating mechanisms, GLP-1 and amylin, in a single molecule, and it comes…
What’s Coming After Ozempic and Zepbound: The 2026 Weight Loss Drug Pipeline
The obesity drug pipeline in 2026 is the most active it has ever been, with several new medications either just approved or moving through…
What Is Survodutide? The GLP-1/Glucagon Drug for Obesity and Liver Disease
Survodutide is an investigational once-weekly injectable from Boehringer Ingelheim and Zealand Pharma, being developed for both obesity and liver disease. It’s a dual agonist…
Orforglipron vs Ozempic: Pill vs Injection for Weight Loss
Orforglipron and Ozempic both harness GLP-1 to reduce appetite and drive weight loss, but they differ in two ways that matter day to day:…
What Is Orforglipron? The First Oral GLP-1 Pill for Weight Loss
Orforglipron, sold under the brand name Foundayo, is a once-daily GLP-1 pill for weight loss from Eli Lilly, and it reached a milestone in…
CagriSema vs Zepbound: What the Trial Data Suggests
CagriSema and Zepbound are two of the most powerful weight-loss approaches in obesity medicine, and on trial data they land in a broadly similar…
What Is CagriSema? Cagrilintide and Semaglutide Explained
CagriSema is an investigational once-weekly injectable from Novo Nordisk that combines two different weight-loss ingredients in one shot: cagrilintide, an amylin analog, and semaglutide,…
